389 related articles for article (PubMed ID: 21034822)
1. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response.
DiNapoli JM; Yang L; Samal SK; Murphy BR; Collins PL; Bukreyev A
Vaccine; 2010 Dec; 29(1):17-25. PubMed ID: 21034822
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.
Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2017 May; 91(10):. PubMed ID: 28250127
[TBL] [Abstract][Full Text] [Related]
3. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.
Bukreyev AA; Dinapoli JM; Yang L; Murphy BR; Collins PL
Virology; 2010 Apr; 399(2):290-8. PubMed ID: 20129638
[TBL] [Abstract][Full Text] [Related]
4. Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.
Meyer M; Garron T; Lubaki NM; Mire CE; Fenton KA; Klages C; Olinger GG; Geisbert TW; Collins PL; Bukreyev A
J Clin Invest; 2015 Aug; 125(8):3241-55. PubMed ID: 26168222
[TBL] [Abstract][Full Text] [Related]
5. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals.
Yang L; Sanchez A; Ward JM; Murphy BR; Collins PL; Bukreyev A
Virology; 2008 Aug; 377(2):255-64. PubMed ID: 18570964
[TBL] [Abstract][Full Text] [Related]
6. A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice.
Chen T; Li D; Song Y; Yang X; Liu Q; Jin X; Zhou D; Huang Z
Antiviral Res; 2017 Sep; 145():54-59. PubMed ID: 28733113
[TBL] [Abstract][Full Text] [Related]
7. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
8. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
[TBL] [Abstract][Full Text] [Related]
9. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
10. Heterologous prime-boost regimens with HAdV-5 and NDV vectors elicit stronger immune responses to Ebola virus than homologous regimens in mice.
Zhao W; Zhang P; Bai S; Lv M; Wang J; Chen W; Yu Q; Wu J
Arch Virol; 2021 Dec; 166(12):3333-3341. PubMed ID: 34591172
[TBL] [Abstract][Full Text] [Related]
11. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine.
Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A
mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
13. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
14. Successful topical respiratory tract immunization of primates against Ebola virus.
Bukreyev A; Rollin PE; Tate MK; Yang L; Zaki SR; Shieh WJ; Murphy BR; Collins PL; Sanchez A
J Virol; 2007 Jun; 81(12):6379-88. PubMed ID: 17428868
[TBL] [Abstract][Full Text] [Related]
15. Novel avian paramyxovirus-based vaccine vectors expressing the Ebola virus glycoprotein elicit mucosal and humoral immune responses in guinea pigs.
Yoshida A; Kim SH; Manoharan VK; Varghese BP; Paldurai A; Samal SK
Sci Rep; 2019 Apr; 9(1):5520. PubMed ID: 30940854
[TBL] [Abstract][Full Text] [Related]
16. Intranasal immunization with recombinant Vaccinia virus Tiantan harboring Zaire Ebola virus gp elicited systemic and mucosal neutralizing antibody in mice.
Xie L; Zai J; Yi K; Li Y
Vaccine; 2019 May; 37(25):3335-3342. PubMed ID: 31076161
[TBL] [Abstract][Full Text] [Related]
17. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
[TBL] [Abstract][Full Text] [Related]
18. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.
Luczkowiak J; Arribas JR; Gómez S; Jiménez-Yuste V; de la Calle F; Viejo A; Delgado R
Virus Res; 2016 Feb; 213():224-229. PubMed ID: 26739425
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
[TBL] [Abstract][Full Text] [Related]
20. Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates.
Bukreyev A; Huang Z; Yang L; Elankumaran S; St Claire M; Murphy BR; Samal SK; Collins PL
J Virol; 2005 Nov; 79(21):13275-84. PubMed ID: 16227250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
